Skip to main content

Nordic Nanovector ASA Stock Forecast, Price & News

0.00 (0.00 %)
(As of 05/14/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive NRNVF News and Ratings via Email

Sign-up to receive the latest news and ratings for Nordic Nanovector ASA and its competitors with MarketBeat's FREE daily newsletter.

About Nordic Nanovector ASA

Nordic Nanovector ASA, a biopharmaceutical company, develops and commercializes therapeutics for haematological cancers. The company's lead product candidate is Betalutin, an antibody-radionuclide-conjugate, which is in Phase 2b clinical trial for the treatment of patients with non-hodgkin lymphoma, a life-threatening blood cancer. Nordic Nanovector ASA has collaboration agreements with Paul Scherrer Institute; Areva Med; LegoChemBio; and Heidelberg Pharma. The company was formerly known as Nordic Nanovector AS and changed its name to Nordic Nanovector ASA in 2014. Nordic Nanovector ASA was incorporated in 2009 and is headquartered in Oslo, Norway.


Nordic Nanovector ASA (OTCMKTS:NRNVF) Short Interest Update
Nordic Nanovector ASA (OTCMKTS:NRNVF) Short Interest Update
April 30, 2021 |
Nordic Nanovector ASA reports Q4 results
Nordic Nanovector ASA reports Q4 results
February 18, 2021 |
See More Headlines

Industry, Sector and Symbol

Industry Biotechnology
Phone47 22 18 33 01
Year FoundedN/A

Sales & Book Value

Annual SalesN/A





Next Earnings DateN/A
OptionableNot Optionable


Overall MarketRank

0.00 out of 5 stars

Medical Sector

1965th out of 2,039 stocks

Biotechnology Industry

141st out of 157 stocks

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Nordic Nanovector ASA (OTCMKTS:NRNVF) Frequently Asked Questions

Is Nordic Nanovector ASA a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nordic Nanovector ASA in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" Nordic Nanovector ASA stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NRNVF, but not buy additional shares or sell existing shares.
View analyst ratings for Nordic Nanovector ASA
or view top-rated stocks.

What stocks does MarketBeat like better than Nordic Nanovector ASA?

Wall Street analysts have given Nordic Nanovector ASA a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Nordic Nanovector ASA wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Nordic Nanovector ASA?

Nordic Nanovector ASA saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 341,900 shares, an increase of 93.2% from the March 31st total of 177,000 shares. Based on an average trading volume of 0 shares, the days-to-cover ratio is presently ∞ days.
View Nordic Nanovector ASA's Short Interest

Who are Nordic Nanovector ASA's key executives?

Nordic Nanovector ASA's management team includes the following people:
  • Dr. Lars Nieba Ph.D., Interim CEO & Chief Technology Officer (Age 52, Pay $91k)
  • Ms. Malene Brondberg, Chief Financial Officer (Age 48, Pay $342.84k)
  • Dr. Marco Renoldi, Chief Operating Officer (Age 64, Pay $483.55k)
  • Dr. Jostein Dahle, Chief Scientific Officer (Age 48, Pay $267.04k)
  • Ms. Rosemarie Corrigan, Chief Quality Officer (Age 56, Pay $380.97k)
  • Dr. Gabriele Elbl, VP Global Regulatory Affairs (Age 60, Pay $99.78k)
  • Mr. Fredrik Haavind, Head of Legal & Compliance
  • Ms. Maureen Deehan, Head of Corp. Devel. & Strategy
  • Dr. Reza Safaei, Head of Medical Affairs
  • Dr. Mark Wright, Head of Manufacturing

Who are some of Nordic Nanovector ASA's key competitors?

What is Nordic Nanovector ASA's stock symbol?

Nordic Nanovector ASA trades on the OTCMKTS under the ticker symbol "NRNVF."

How do I buy shares of Nordic Nanovector ASA?

Shares of NRNVF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Nordic Nanovector ASA's stock price today?

One share of NRNVF stock can currently be purchased for approximately $1.64.

How many employees does Nordic Nanovector ASA have?

Nordic Nanovector ASA employs 34 workers across the globe.

What is Nordic Nanovector ASA's official website?

The official website for Nordic Nanovector ASA is

How can I contact Nordic Nanovector ASA?

The company can be reached via phone at 47 22 18 33 01.

This page was last updated on 5/15/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.